ReviewCancer immunology, immunotherapy : CII2016
Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 43 citations in OpenAlex.
- Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood advances · 2026Trial
- Review
- The role of miR-3917/HLA-DRB1 in Th17 cell differentiation affects chronic periodontitis.Odontology · 2026Article
- Multifaceted Roles of IL-26 in Physiological and Pathological Conditions.International journal of molecular sciences · 2025Review
- A New Method of Canine CD4International journal of molecular sciences · 2025Article
- Clinicopathological features and prognostic significance of TAF1L in gastric cancer.BMC gastroenterology · 2024Article
- A novel intranasal peptide vaccine inhibits non-small cell lung cancer with KRAS mutation.Cancer gene therapy · 2024Article
- Role of autoreactive Tc17 cells in the pathogenesis of experimental autoimmune encephalomyelitis.Neuroprotection (Chichester, England) · 2024Article
- Microglia and Microbiome-Gut-Brain Axis.Advances in neurobiology · 2024Review
- The Tumor Stemness Indice mRNAsi can Act as Molecular Typing Tool for Lung Adenocarcinoma.Biochemical genetics · 2023Article
- Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target.Cancers · 2023Review
- Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- T cells in health and disease.Signal transduction and targeted therapy · 2023Review
- Myeloid-derived suppressor cells promote the formation of abdominal aortic aneurysms through the IL-3-ICOSL-ICOS axis.BBA advances · 2023Article
- The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment.Frontiers in immunology · 2023Review
- Canine B Cell Lymphoma- and Leukemia-Derived Extracellular Vesicles Moderate Differentiation and Cytokine Production of T and B Cells In Vitro.International journal of molecular sciences · 2022Article
- Article
- CAR-T Cell Performance: How to Improve Their Persistence?Frontiers in immunology · 2022Review
- Inflammatory Mediators and Gut Microbial Toxins Drive Colon Tumorigenesis by IL-23 Dependent Mechanism.Cancers · 2021Article
- IL-17-Producing Cells in Tumor Immunity: Friends or Foes?Immune network · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Cancer immunotherapy is one the most effective approaches for treating patients with tumors, as it bolsters the generation and persistence of memory T cells. In preclinical work, it has been reported that adoptively transferred CD4+ and CD8+ lymphocytes that secrete IL-17A (i.e., Th17 and Tc17 cells) regress tumors to a greater extent than IFN-γ(+)Th1 or Tc1 cells in vivo. Herein, we review the mechanisms underlying how infused Th17 and Tc17 cells regress established malignancies in clinically relevant mouse models of cancer. We also discuss how unique signaling cues--such as co-stimulatory molecules (ICOS and 41BB), cytokines (IL-12 and IL-23) or pharmaceutical reagents (Akt inhibitors, etc.)--can be exploited to bolster the therapeutic potential of IL-17(+) lymphocytes with an emphasis on using this knowledge to improve next-generation clinical trials for patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.